ANTOINE YVER - 01 Feb 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Medical Officer
Signature
/s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
01 Feb 2022
Transactions value $
$0
Form type
4
Filing time
03 Feb 2022, 17:30:17 UTC
Previous filing
27 May 2021
Next filing
19 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +200K $0.00 200K 01 Feb 2022 Ordinary Shares 200K $9.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 16,664 shares subject to such option shall vest and become exercisable on June 1,2022 and the remaining 183,336 shares subject to such option shall vest and become exercisable in 44 substantially equal installments on each monthly anniversary thereafter.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.